Physicians' Academy for Cardiovascular Education

PPAR gamma activation Clinical evidence

Slides (presentation) - Dec. 24, 2012

Slide lecture program (6 slides): View & Download

  1. Evolution of clinical evidence supporting PPAR gamma activation
  2. Anticipated results from large multicenter trials in (pre)diabetes
  3. PROactive: Study Design
  4. PROactive Baseline Characteristics
  5. PROactive CV history at baseline
  6. PROactive CV medications at baseline
  7. Time to primary composite endpoint
  8. Significant reduction in secondary outcome
  9. Time to all-cause death, non-fatal MI, stroke or ACS
  10. Time to permanent insulin use
  11. PROactive Subgroup analysis – Previous MI
  12. PROactive Subgroup analysis – Previous stroke
  13. PROactive HF hospitalization and mortality
  14. TZDs associated with lower mortality
  15. PROactive in perspective
  16. PROactive vs landmark clinical trials: Comparative benefit in patients with diabetes
PPAR gamma activation Clinical evidence
Evolution of clinical evidence supporting PPAR gamma activation
Anticipated results from large multicenter trials in (pre)diabetes
PROactive: Study Design
PROactive Baseline Characteristics
PROactive CV history at baseline
PROactive CV medications at baseline
Time to primary composite endpoint
Significant reduction in secondary outcome
Time to all-cause death, non-fatal MI, stroke or ACS
Time to permanent insulin use
PROactive Subgroup analysis – Previous MI
PROactive Subgroup analysis – Previous stroke
PROactive HF hospitalization and mortality
TZDs associated with lower mortality
Summary
PROactive in perspective
PROactive vs landmark clinical trials

Share this page with your colleagues and friends: